Kathleen N. Moore, MD, MS

home / authors / kathleen-n-moore-md-ms

Articles

Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.

Exploring CDK4/6 Endocrine Therapy for Low-Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
February 27th 2025

Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.

The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.

Evaluating Frontline Treatment Options for Low-Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
February 26th 2025

The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.

Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.

Distinguishing Low-Grade Serous Ovarian Cancer From Other Ovarian Cancer Types

Kathleen N. Moore, MD, MS
February 25th 2025

Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
PALOMA-3: Clinical Implications
Published: February 11th 2025 | Updated: February 28th 2025
PALOMA-3: Clinical Implications